Alpha Tau Medical (NASDAQ:DRTS) Earns “Buy” Rating from HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 243.51% from the company’s previous close.

Alpha Tau Medical Price Performance

Shares of DRTS opened at $2.62 on Monday. The firm’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $2.80. The company has a market capitalization of $183.20 million, a P/E ratio of -6.09 and a beta of 0.87. Alpha Tau Medical has a 1-year low of $1.75 and a 1-year high of $4.39.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). On average, equities analysts anticipate that Alpha Tau Medical will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Levin Capital Strategies L.P. grew its position in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after acquiring an additional 7,189 shares during the last quarter. Northern Trust Corp grew its position in Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after acquiring an additional 26,800 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.